Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular CarcinomaAntiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
- Other Titles
- Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
- Authors
- Huang, Daniel Q.; Hoang, Joseph K.; Kamal, Rubayet; Tsai, Pei-Chien; Toyoda, Hidenori; Yeh, Ming-Lun; Yasuda, Satoshi; Leong, Jennifer; Maeda, Mayumi; Huang, Chung-Feng; Jun, Dae Won; Ishigami, Masatoshi; Tanaka, Yasuhito; Uojima, Haruki; Ogawa, Eiichi; Abe, Hiroshi; Hsu, Yao-Chun; Tseng, Cheng-Hao; Alsudaney, Manaf; Yang, Ju Dong; Yoshimaru, Yoko; Suzuki, Takanori; Liu, Joanne K.; Landis, Charles; Dai, Chia-Yen; Huang, Jee-Fu; Chuang, Wan-Long; Schwartz, Myron; Dan, Yock Young; Esquivel, Carlos; Bonham, Andrew; Yu, Ming-Lung; Nguyen, Mindie H.
- Issue Date
- Mar-2024
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.42, no.7, pp 790 - 799
- Pages
- 10
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 42
- Number
- 7
- Start Page
- 790
- End Page
- 799
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/194921
- DOI
- 10.1200/JCO.23.00757
- ISSN
- 0732-183X
1527-7755
- Abstract
- PURPOSE There are limited data on antiviral treatment utilization and its impact on long-term outcomes of hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after hepatic resection. We aimed to determine the utilization and impact of antivirals in HBV- and HCV-related HCC. METHODS This cohort study included 1,906 participants (1,054 HBV-related HCC and 852 HCV-related HCC) from 12 international sites. All participants had HBV- or HCV-related HCC and underwent curative surgical resection. The primary outcome was the utilization of antiviral therapy, and the secondary outcome was long-term overall survival (OS). RESULTS The mean (+/- standard deviation [SD]) age was 62.1 (+/- 11.3) years, 74% were male, and 84% were Asian. A total of 47% of the total cohort received antiviral therapy during a mean (+/- SD) follow-up of 5.0 (+/- 4.3) years. The overall antiviral utilization for participants with HBV-related HCC was 57% and declined over time, from 65% before 2010, to 60% from 2010 to 2015, to 47% beyond 2015, P < .0001. The overall utilization of antivirals for HCV-related HCC was 35% and increased over time, from 24% before 2015 to 74% from 2015 and beyond, P < .0001. The 10-year OS was lower in untreated participants for both HBV (58% v 61%) and HCV participants (38% v 82%; both P < .0001). On multivariable Cox regression analysis adjusted for relevant confounders, antiviral therapy initiated before or within 6 months of HCC diagnosis was independently associated with lower mortality in both HBV- (adjusted hazard ratio [aHR], 0.60 [95% CI, 0.43 to 0.83]; P = .002) and HCV-related HCC (aHR, 0.18 [95% CI, 0.11 to 0.31]; P < .0001). CONCLUSION Antiviral therapy is associated with long-term survival in people with HBV- or HCV-related HCC who undergo curative resection but is severely underutilized.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/194921)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.